中国医药
中國醫藥
중국의약
China Medicine
2015年
12期
1818-1821
,共4页
肾功能衰竭%尿毒清颗粒%血液透析滤过%钙磷代谢%甲状旁腺激素
腎功能衰竭%尿毒清顆粒%血液透析濾過%鈣燐代謝%甲狀徬腺激素
신공능쇠갈%뇨독청과립%혈액투석려과%개린대사%갑상방선격소
Renal failure%Niaoduqing particles%Hemodiafiltration%Calcium-phosphorus metabolism%Parathyroid hormone
目的 探讨尿毒清颗粒对终末期肾功能衰竭维持性血液透析患者钙磷代谢及甲状旁腺激素水平的影响.方法 选取201 1年10月至2014年2月于北京积水潭医院血液净化中心进行血液透析治疗的终末期肾功能衰竭患者62例,完全随机分为观察组和对照组,各31例.对照组常规行血液透析治疗;观察组在常规血液透析基础上口服尿毒清颗粒,1袋(5.0 g)/次,4次/d.2组疗程均为6个月.比较2组患者治疗前后血钙、血磷及甲状旁腺激素水平,同时比较2组患者皮肤瘙痒缓解程度和不良反应发生情况.结果 观察组治疗6个月后血钙高于治疗前[(2.24±0.17) mmol/L比(1.87±0.19) mmol/L],血磷及甲状旁腺激素水平均低于治疗前[(1.53 ±0.14) mmol/L比(1.81 ±0.12) mmol/L,(202 ±40) ng/L比(244±42) ng/L],差异均有统计学意义(均P＜0.05).对照组治疗6个月后血钙水平高于治疗前[(2.11±0.16) mmol/L比(1.89 ±0.21) mmol/L],血磷水平低于治疗前[(1.66±0.11) mmol/L比(1.82 ±0.13) mmol/L],差异有统计学意义(P＜0.05),甲状旁腺激素水平与治疗前比较,差异无统计学意义[(238 ±43) ng/L比(244±42) ng/L] (P ＞0.05).治疗6个月后,观察组血钙水平高于对照组,血磷及甲状旁腺激素水平低于对照组,差异均有统计学意义(均P＜0.05).观察组皮肤瘙痒症状总缓解率明显高于对照组[83.9％ (26/31)比51.6％ (16/31)],差异有统计学意义(x2 =7.485,P＜0.05).所有患者均无发热、皮疹等过敏反应,无胃肠道、神经系统等严重不良反应.结论 尿毒清颗粒对纠正终末期肾功能衰竭维持性血液透析患者钙磷代谢紊乱、降低甲状旁腺激素水平及改善皮肤瘙痒均有一定疗效.
目的 探討尿毒清顆粒對終末期腎功能衰竭維持性血液透析患者鈣燐代謝及甲狀徬腺激素水平的影響.方法 選取201 1年10月至2014年2月于北京積水潭醫院血液淨化中心進行血液透析治療的終末期腎功能衰竭患者62例,完全隨機分為觀察組和對照組,各31例.對照組常規行血液透析治療;觀察組在常規血液透析基礎上口服尿毒清顆粒,1袋(5.0 g)/次,4次/d.2組療程均為6箇月.比較2組患者治療前後血鈣、血燐及甲狀徬腺激素水平,同時比較2組患者皮膚瘙癢緩解程度和不良反應髮生情況.結果 觀察組治療6箇月後血鈣高于治療前[(2.24±0.17) mmol/L比(1.87±0.19) mmol/L],血燐及甲狀徬腺激素水平均低于治療前[(1.53 ±0.14) mmol/L比(1.81 ±0.12) mmol/L,(202 ±40) ng/L比(244±42) ng/L],差異均有統計學意義(均P＜0.05).對照組治療6箇月後血鈣水平高于治療前[(2.11±0.16) mmol/L比(1.89 ±0.21) mmol/L],血燐水平低于治療前[(1.66±0.11) mmol/L比(1.82 ±0.13) mmol/L],差異有統計學意義(P＜0.05),甲狀徬腺激素水平與治療前比較,差異無統計學意義[(238 ±43) ng/L比(244±42) ng/L] (P ＞0.05).治療6箇月後,觀察組血鈣水平高于對照組,血燐及甲狀徬腺激素水平低于對照組,差異均有統計學意義(均P＜0.05).觀察組皮膚瘙癢癥狀總緩解率明顯高于對照組[83.9％ (26/31)比51.6％ (16/31)],差異有統計學意義(x2 =7.485,P＜0.05).所有患者均無髮熱、皮疹等過敏反應,無胃腸道、神經繫統等嚴重不良反應.結論 尿毒清顆粒對糾正終末期腎功能衰竭維持性血液透析患者鈣燐代謝紊亂、降低甲狀徬腺激素水平及改善皮膚瘙癢均有一定療效.
목적 탐토뇨독청과립대종말기신공능쇠갈유지성혈액투석환자개린대사급갑상방선격소수평적영향.방법 선취201 1년10월지2014년2월우북경적수담의원혈액정화중심진행혈액투석치료적종말기신공능쇠갈환자62례,완전수궤분위관찰조화대조조,각31례.대조조상규행혈액투석치료;관찰조재상규혈액투석기출상구복뇨독청과립,1대(5.0 g)/차,4차/d.2조료정균위6개월.비교2조환자치료전후혈개、혈린급갑상방선격소수평,동시비교2조환자피부소양완해정도화불량반응발생정황.결과 관찰조치료6개월후혈개고우치료전[(2.24±0.17) mmol/L비(1.87±0.19) mmol/L],혈린급갑상방선격소수평균저우치료전[(1.53 ±0.14) mmol/L비(1.81 ±0.12) mmol/L,(202 ±40) ng/L비(244±42) ng/L],차이균유통계학의의(균P＜0.05).대조조치료6개월후혈개수평고우치료전[(2.11±0.16) mmol/L비(1.89 ±0.21) mmol/L],혈린수평저우치료전[(1.66±0.11) mmol/L비(1.82 ±0.13) mmol/L],차이유통계학의의(P＜0.05),갑상방선격소수평여치료전비교,차이무통계학의의[(238 ±43) ng/L비(244±42) ng/L] (P ＞0.05).치료6개월후,관찰조혈개수평고우대조조,혈린급갑상방선격소수평저우대조조,차이균유통계학의의(균P＜0.05).관찰조피부소양증상총완해솔명현고우대조조[83.9％ (26/31)비51.6％ (16/31)],차이유통계학의의(x2 =7.485,P＜0.05).소유환자균무발열、피진등과민반응,무위장도、신경계통등엄중불량반응.결론 뇨독청과립대규정종말기신공능쇠갈유지성혈액투석환자개린대사문란、강저갑상방선격소수평급개선피부소양균유일정료효.
Objective To explore the effect of Niaoduqing particles on calcium-phosphorus metabolism and parathyroid hormone in patients of end-stage renal failure with maintenance hemodialysis.Methods Totally 62 patients with end-stage renal failure who underwent hemodialysis from October 2011 to February 2014 were randomly divided into observation group (31 cases) orally administrated with Niaoduqing particles (5.0 g/time,4 times/d) in addition to routine hemodialysis, and control group (31 cases) given routine hemodialysis.The treatment was lasted for 6 months, then the changes of serum calcium, serum phosphate and parathyroid hormone (PTH) were detected and compared between the two groups, the degree of pruritus releasing and incidence of adverse reactions were also observed.Results After treatment, the level of serum calcium was significantly increased, the levels of serum phosphate and PTH were significantly reduced compared with those before treatment in observation group [(2.24 ±0.17) mmol/L vs (1.87 ±0.19) mmol/L, (1.53 ±0.14) mmol/L vs (1.81 ±0.12) mmol/L, (202 ± 40) ng/L vs (244 ± 42) ng/L] (P ＜ 0.05);after treatment, the level of serum calcium was significantly increased and the level of serum phosphate was significantly reduced compared with those before treatment in control group [(2.11 ± 0.16) mmol/L vs (1.89 ± 0.21) mmol/L, (1.66 ± 0.11) mmol/L vs (1.82 ±0.13) mmol/L] (P ＜0.05), while no change was found for PHT [(238 ±43) ng/L vs (244 ±42) ng/L](P ＞ 0.05).After treatment, the levels of serum calcium and PTH in observation group was significantly different with those in control group (all P ＜ 0.05).The releasing rate of pruritus in observation group was significantly higher than that in control group [83.9％ (26/31) vs 51.6％ (16/31)] (x2 =7.485, P ＜0.05).No fever, allergic reaction such as rash, gastrointestinal and nervous severe adverse reactions were found.Conclusion Niaoduqing particles can remedy the disorder of calcium-phosphorus metabolism, reduce the level of parathyroid hormone and improve pruritus in patient with maintenance hemodialysis.
